Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) to a hold rating in a research note published on Thursday morning,Zacks.com reports.

A number of other research analysts have also commented on BIOVF. HC Wainwright started coverage on shares of Swedish Orphan Biovitrum in a research note on Wednesday. They set a “buy” rating on the stock. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. Danske lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. Finally, BNP Paribas Exane upgraded shares of Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Swedish Orphan Biovitrum currently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

OTCMKTS BIOVF opened at $47.48 on Thursday. Swedish Orphan Biovitrum has a 12 month low of $27.06 and a 12 month high of $47.48. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59. The firm has a market capitalization of $16.90 billion, a PE ratio of 158.25 and a beta of 0.34. The company’s 50 day simple moving average is $40.85 and its 200 day simple moving average is $37.43.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 17.23%. The business had revenue of $755.76 million for the quarter, compared to analyst estimates of $749.76 million. As a group, equities research analysts forecast that Swedish Orphan Biovitrum will post 2.26 EPS for the current fiscal year.

Swedish Orphan Biovitrum News Roundup

Here are the key news stories impacting Swedish Orphan Biovitrum this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Swedish Orphan Biovitrum and projected rising earnings through 2026 and 2027, including $2.26 EPS for FY2026 and $3.49 EPS for FY2027, which may reinforce investor confidence. Swedish Orphan Biovitrum stock page
• Neutral Sentiment: The new report mainly updated quarterly and annual EPS estimates for multiple future periods, but it did not include a fresh business update, catalyst, or management guidance change. Swedish Orphan Biovitrum stock page

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.